摘要
血栓性疾病的致死率、致残率很高,对人类健康危害极大。溶栓是治疗血栓疾病的有效方法。目前临床使用的溶栓剂有第一代链激酶(SK)、尿激酶(UK)及第二代酰化纤溶酶原链激酶激活剂(APSAC),组织型纤溶酶原激活物(t—PA)及单链尿激酶(SCU—PA,Pro—UK)。近年来在应用上述药物纤溶栓治疗方面取得了较大成功。
出处
《血栓与止血学》
1994年第2期85-88,共4页
Chinese Journal of Thrombosis and Hemostasis
参考文献15
-
1Lijene HR.Biochemical and functional characterization of human t-PA variants obtained by deletion and/or duplication of structural/functional domains. Journal of Biological Chemistry . 1990
-
2Imura Y.Thrombolytle and pharmacokinetic properties of immuncojugate of scu-PA and bispeeiflc monoclonal ab against fibrin and against u-PA in beboons. Blood . 1992
-
3Dewerchin M.Effete of chemical conjugation of recombinant single-chain urokinase-type plesminogan activutor with monoclonal antipletelet antibodies on pletlet aggregation and on plasma clot lysis in vitro and in vivo. Blood . 1991
-
4Stassen JM.Abispecific monoclonal antibody against human fibrin and against urokinase-type-plesminogen activator enhances clot lysis. Thrombosis and Haemostasis . 1991
-
5Sobel BE.Augmented and sustained plasma enncentrations after Intramuscular injections of molecular variants and deglycosylated forms of t-PA. Circulation . 1990
-
6Collen D.Thrombolytic and pharmacokinetic properties of human t-PA variants, obtained by deletion and/or duplication of stuctural/functional domains, In a hamster pulmonary embolism model. Thrombosis and Haemostasis . 1991
-
7Dewerchin M.Thromboiytie and pharmakinetic properties of a recombinant chimeric plasminogen actibator consisting of a fibrin fragment D-Dtmer specific humanized monoclonal antibody and a trancated sigle-chain urokinase. Thrombosis and Haemostasis . 1992
-
8Declerck PJ.A monoclonal antibody specific for two chain urokinase type piasminogen activator, application to the study of the mechanism of clot lysis with scu-PA in plasms. Blood . 1990
-
9Vandamme AM.Characterization of recombinant chimeric plasminogen activator composed of a fibrin fragment D-dimer specific humanfzed monocional entity and a truncated scu-PA. European Journal of Biochemistry . 1992
-
10Califf RM.The Clinical risks of thrombolysis. The American Journal of Cardiology . 1992
同被引文献18
-
1Yu ITS, Li W, Wong TW. Effects of age, period and cohort on acute myocardial infarction mortality in Hong Kong[J]. International Journal of Cardiology,2004,97:63.
-
2Haug T, Klara SK, Olsen QM, et. al. Antibacterial activities in various tissues of the horse mussel, Modiolus modiolus[J]. Journal of Inver Sandsdalen E. , Styrvol tebrate Pathology, 2004, 85: 112.
-
3Chisholm JRS, Smith VJ. Comparison of antibacterial activity in the hemocytes of different crustacean species[J]. Comparative Biochemistry and Physiology, 1995,110A (1):39.
-
4Yokokawa F, Sameshima H, In Y,et al. Total synthesis and conformational studies of ceratospongamide, a bioactive cyclic heptapeptide from marine origin[J]. Tetrahedron, 2002,58: 8127.
-
5Shahidi F, JanakKamil YVA. Enzymes from fish and aquatic invertebrates and their application in the food industry[J]. Trends in Food Science & Technology,2001,12:435.
-
6Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4[J]. Nature,1970,227:680.
-
7Zhao J, Li L, Wu C, et al. Hydrolysis of fibrinogen and plasminogen by immobilized earthworm fibrinolytic enzyme Ⅱ from Eisenia fetida[J]. International Journal of Biological Macromolecules, 2003,32: 165.
-
8Hu RL, Zhang SF, Liang H. Y, et al. Codon optimization, expression, and characterization of recombinant lumbrokinase in goat milk[J]. Protein Expression and Purifcation,2004, 37: 83.
-
9Tang Y, Liang DC, Jiang T, et al. Crystal structure of earthworm fibrinolytic enzyme component A: revealing the structural determinants of its dual fibrinolytie activity[J]. Journal of Molecular Biology,2002,321: 57.
-
10Ageno W. Treatment of venous thromboembolism[J]. Thrombosis Research ,2000,97:V63.
二级引证文献13
-
1姜楠,刘瑜,董小黎,宋爱利,刘国贞.脑血栓溶栓治疗新进展[J].实用医学杂志,2007,23(21):3464-3465. 被引量：3
-
2崔恩贤,龙丽辉,张连强,张兵,梅颖,曹永孝.黄栌复方的体外抗凝血和溶血栓活性研究[J].中药材,2009,32(5):764-767. 被引量：5
-
3崔恩贤,龙丽辉,杨小梅,张洁琼,邵红英,刘琳丽.漆黄素、槲皮素的体外抗凝血和溶血栓作用[J].中药材,2009,32(7):1111-1113. 被引量：3
-
4崔恩贤,龙丽辉,马丽霞,楚丽雅,赵俊仙,刘琳丽.黄栌各部位提取物体外抗凝血及抗血栓作用[J].中药材,2009,32(9):1438-1441. 被引量：3
-
5林芬,谢和.产酱香细菌中高活性纤溶酶菌株的筛选[J].食品科学,2010,31(17):258-262. 被引量：12
-
6初金鑫,蔡文娣,韩宝芹,刘万顺,陈丽梅,连波.单环刺螠纤溶酶UFE-Ⅰ的性质和溶栓活性[J].天然产物研究与开发,2010,22(4):661-664. 被引量：9
-
7车长远,刘海梅,孙舒扬,贡汉生,王雷,王功芹.海肠保健低温火腿肠的研制[J].食品科学,2012,33(16):334-337.
-
8霍伟敏,段文丽,柳军,尚靖.β-榄香烯抗凝血溶血栓活性研究[J].亚太传统医药,2013,9(8):30-33. 被引量：9
-
9范荟,韦荣编,宋茹.微生物发酵制备纤溶因子的研究进展[J].安徽农业科学,2013,41(31):12452-12454. 被引量：1
-
10于文淼,刘凤叶,王乐栋,朱东国,贡汉生.冷冻干燥和热风干燥单环刺螠产品品质分析[J].食品工业科技,2014,35(22):102-105. 被引量：4
-
1兰标,郭晔堃,钟静芬,时惠麟.新型口服抗凝药临床一览[J].上海医药,2014,35(21):61-65. 被引量：2
-
2张益民,李幼姬.低分子量肝素在血液透析患者中的安全性及效果[J].中国中西医结合肾病杂志,2005,6(8):456-456. 被引量：4
-
3Anderson JL,叶金朝.APSAC治疗急性心肌梗塞的现状[J].国外医药（合成药．生化药．制剂分册）,1989,10(6):341-342.
-
4常静.口服第十凝血因子直接抑制剂年内将进入Ⅲ期临床[J].中华医学信息导报,2005,20(22):18-18.
-
5杨斌武.低分子量肝素与心血管疾病[J].兰州医学院学报,2002,28(4):91-93.
-
6肖国伟,宋后燕,丁声颂.一种新的溶栓药物——APSAC[J].国外医学（分子生物学分册）,1992,14(1):35-37.
-
7江明性.溶栓药研究的发展[J].现代诊断与治疗,1994,5(5):309-311. 被引量：1
-
8周泉生,阮长耿.Defibrotide预防和治疗血栓疾病的研究进展[J].心血管病学进展,1991,12(2):107-110. 被引量：1
-
9曾冲,朱树雄.APSAC干预死亡率研究[J].岭南心血管病杂志,2003,9(2):120-120.
-
10李秀珍,张用书,程度胜,刘凤云.低分子量尿激酶与血纤蛋白粘附肽(12肽)融合表达及特性分析[J].军事医学科学院院刊,1997,21(3):169-172.
